Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomes

Pharmaceutical Research

Volumn 16, Issue 6, 1999, Pages 841-846

  Bandak, Suzan ^a   Ramu, Avner ^a   Barenholz, Yechezkel ^b   Gabizon, Alberto ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Doxorubicin; Liposomes; Photodegradation; UV A light

Indexed keywords

DOXORUBICIN; LIPOSOME; MACROGOL;

ARTICLE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; ENCAPSULATION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PH MEASUREMENT; PHOTODEGRADATION; PRIORITY JOURNAL; ULTRAVIOLET IRRADIATION;

ANTINEOPLASTIC AGENTS; CAPSULES; DOXORUBICIN; DRUG CARRIERS; LIPOSOMES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; ULTRAVIOLET RAYS;

EID: 0032980270     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018869818282     Document Type: Article

References (24)

1. 1. G. E. Riggs and N. R. Bachur. Clinical pharmacokinetics of anthracycline antibiotics. In M. M. Ames, G. Powis and J. S. Kovach (eds.), Pharmacokinetics of anticancer agents in humans. Eisevier, Amsterdam, 1983, pp. 229-278.
2. 2. N. Tavoloni, M. A. Guarino, and D. P. Berk. Photolytic degradation of adriamycin. J. Pharm. Pharmacol. 32:860-862 (1980).
3. 3. A. J. Carmichael, M. M. Mossoba, and P. Riesz. Photodegeneration of superoxide by adriamycin and daunomycin: An electron spin resonance and spin trapping study. FEBS Lett. 164:401-405 (1983).
4. 4. A. J. Carmichael and P. Riesz. Photoinduced reaction of anthraquinone anti-tumor agents with peptides and nucleic acid bases: an electron spin resonance and spin trapping study. Arch. Biochem. Biophys. 237:433-444 (1985).
5. 5. M. J. Wood, W. J. Irwin, and D. K. Scott. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high performance liquid chromatography. J. Clin. Pharm. Ther. 15:291-300 (1990).
6. 6. M. A. Le Bot, C. Riche, Y. Guedes, D. Kernaleguen, S. Simon, and J. M. Begue. Study of doxorubicin photodegradation in plasma, urine and cell culture media by HPLC. Biomed. Chromatogr. 2:242-244 (1988).
7. 7. L. Boomgaars, G. Sriya, K. Shannon, and A. Ramu. The inactivation of doxorubicin by long ultraviolet light. Cancer Chemother. Pharmacol. 40:506-512 (1997).
8. 8. D. Lasic and F. Martin. Stealth Liposomes, C.R.C. Press, Boca Raton, Florida, 1995.
9. 9. D. Lasic, F. Martin, A. Gabizon, S. Huang. and D. Papahadjopoulos. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070:187-192 (1991).
10. 10. G. Haran, R. Cohen, L. Bar, and Y. Barenholz. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151:201-215 (1993).
11. 11. A. Gabizon. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 16:285-294 (1995).
12. 12. D. Goren, A. T. Horowitz, S. Zalipsky, M. C. Woodle, Y. Yarden, and 1st. Gabizon. Targeting of stealth liposomes to erbB-2(Her/ 2) receptor: in vitro and in vivo studies. Br. J. Cancer 74: 1749-1756 (1996).
13. 13. G. Storm, L. Van Bloois, M. Brouwer, and D. J. Crommelin. The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochim. Biophys. Acta 818: 343-351 (1985).
14. 14. S. Amselem, A. Gabizon, and Y. Barenholz. Optimization and upscaling of doxorubicin containing liposomes for clinical use. J. Pharm. Sci. 79: 1045-1052 (1990).
15. 15. A. Horowitz, Y. Barenholz, and A. Gabizon. In-vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release. Biochim Biophys. Acta 1109:203-209 (1992).
16. 16. A. Gabizon. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes. Cancer Res. 52:891-896 (1992).
17. nd Edn., CRC Press, Boca Raton, 1993, pp. 527-616.
18. 18. Y. Barenholz and D. Lichtenberg. Liposomes: Preparation, characterization and preservation. In D. Glick (ed.), Methods of Biochemical analysis. John Wiley & Sons, New York, 1988, p. 348.
19. 19. Y. Barenholz, S. Amselem, D. Goren, R. Cohen, D. Gelvan, A. Samuni, E. Golden, and A. Gabizon. Stability of liposomal doxorubicin formulations: Problems and prospects. Med. Res. Rev. 13:449-491 (1993).
20. 20. D. D. Lasic, P. M. Frederik, M. C. A. Stuart, Y. Barenholz, and T. J. McIntosh. Gelation of liposome interior, a novel method for drug encapsulation. FEBS Lett. 312:255-258 (1992).
21. 21. G. Bacic, T. Walzeak, F. Demsar, and H. M. Swartz. Electron spin resonance imaging of tissues with lipid rich areas. Magn. Reson. Med. 8:209-219 (1988).
22. 22. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, R. Cohen, F. Martin, A. Huang, and Y. Barenholz. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol-coated liposomes. Cancer Res. 54:987-992 (1994).
23. 23. M. Janssen, D. J. A. Crommelin, G. Storm, and A. Hulshoff. Doxorubicin decomposition on storage. Effect of pH, type of buffer and liposome encapsulation. Int. J. Pharmaceutics 23:1-11 (1985).
24. 24. A. Gabizon, D. Goren, R. Cohen, and Y. Barenholz. Development of liposomal anthracyclines: From basics to clinical applications. J. Contr. Rel. 53:275-279 (1998).